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Background: To report the occurrence of foveal atrophy and macular hole formation following 
intravitreal ranibizumab with or without photodynamic therapy for choroidal neovascularization 
caused by age-related macular degeneration.
Methods: This was a retrospective, interventional case series, in which 78 eyes of 76 patients 
were treated for wet age-related macular degeneration between February 2007 and August 
2007. Of these, three eyes developed foveal atrophy following treatment. Two eyes underwent 
combination photodynamic therapy and intravitreal ranibizumab, and one eye underwent intra-
vitreal ranibizumab alone. One of the two eyes that underwent combination therapy progressed 
to develop a macular hole.
Results: On the first follow-up visit, all three eyes showed thinning of the fovea on optical coher-
ence tomography. Subsequently, treatment was continued with repeat intravitreal ranibizumab 
injections. At the last follow-up, although choroidal neovascularization regressed in all eyes, 
extensive foveal atrophy developed in two eyes with macular hole formation in one eye.
Conclusion: The possibility of foveal atrophy and macular hole formation must be borne in 
mind before initiating ranibizumab in combination with or without photodynamic therapy. 
However, larger studies with longer follow-up are required to understand such adverse effects 
better.
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Introduction
Macular hole formation has been reported following photodynamic therapy,1   intravitreal 
ranibizumab,2 and intravitreal bevacizumab.3 To determine such adverse events in our 
patients, we reviewed cases of treated wet age-related macular degeneration between 
February 2007 and August 2007. Twenty-five eyes underwent photodynamic therapy 
(Novartis, Basel, Switzerland), 53 eyes underwent intravitreal ranibizumab (Genen-
tech, San Francisco, CA), and four of these eyes underwent a combination of the two 
treatments. Three cases developed foveal atrophy following treatment, and one of 
these progressed to develop macular hole. Two eyes underwent combination therapy, 
and one underwent intravitreal ranibizumab monotherapy. Macular hole formation 
following combination photodynamic therapy and intravitreal ranibizumab has not 
been reported previously.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Case 1
A 74-year-old gentleman presented with decreased vision 
bilaterally. Best corrected visual acuity (BCVA) was 6/18 in 
the right eye and FC 1 m in the left. Biomicroscopic examina-
tion of the fundus revealed choroidal neovascularization in 
the right eye (Figure 1, upper left) and a disciform scar in the 
left. Clinical findings were confirmed on fundus fluorescein 
angiogram (450 Plus IR, Carl Zeiss Meditec AG, Germany, 
Figure 1, upper right and lower right) and optical coherence 
tomography (Stratus Model 3000 Carl Zeiss Meditec AG, 
Germany, Figure 1, lower left). The patient underwent com-
bination photodynamic therapy (50 J/cm2) with intravitreal 
ranibizumab (0.5 mg/0.05 mL) in the right eye. He came 
back two months later, at which time vision had improved 
to 6/12 P. However, optical coherence tomography revealed 
persisting subretinal fluid (Figure 2, left column, middle), and 
intravitreal ranibizumab was repeated. He came back for a 
follow-up six months later (Figure 2, left column, bottom), by 
which time vision had dropped to 6/36. The fundus revealed 
regressed choroidal neovascularization with foveal atrophy, 
confirmed on optical coherence tomography. Thereafter, the 
patient was followed up regularly at three-monthly intervals. 
Twenty-five months after the last intravitreal injection, the 
fundus remained stable and vision was maintained.
Case 2
A 68 year-old gentleman presented with failure of visual 
improvement in the right eye following cataract   surgery. 
BCVA was 6/60 in the right eye and 6/9 in the left. 
  Biomicroscopic examination of the right fundus revealed 
choroidal neovascularization (Figure 3, upper left).   Clinical 
findings were confirmed on fundus fluorescein   angiography 
(Figure 3, upper right and lower right) and optical   coherence 
tomography (Figure 3, lower left). The patient under-
went photodynamic therapy (50 J/cm2) with intravitreal 
  ranibizumab 0.5 mg. One month later, vision was 6/60, 
and the fundus showed choroidal neovascularization 
with foveal thinning, which was confirmed on optical 
Figure1 Case 1: Color fundus photograph of the right eye (upper left) shows a 
grayish-brown  subfoveal  lesion  suggestive  of  choroidal  neovascular  membrane. 
Early hyperfluoresence with intense late staining on fundus fluorescein angiography 
confirms the presence of predominantly classic choroidal neovascularization (upper 
right and lower right). Optical coherence tomography scan reveals the presence of 
a high reflective, spindle-shaped lesion abutting the fovea with increased overlying 
retinal thickness and intraretinal cystoid spaces (lower left).
Figure 2 sequential comparison of optical coherence tomography scans over time 
for the three study eyes. Column 1 denotes Case 1: At presentation (left, top), 
two months after initial treatment (left, middle), and at last follow-up (left, bottom). 
Column 2 denotes Case 2: At presentation (central, top), four weeks after initial 
treatment  (central,  middle),  and  at  last  follow-up  (central,  bottom).  Column  3 
denotes Case 3: At presentation (right, top), four weeks after initial treatment (right, 
middle), and at last follow-up (right, bottom). Cases 1 and 3 reveal progressive 
retinal thinning at the macula, while Case 2 reveals retinal thinning with evolution of 
full- thickness macular hole.
Figure 3 Case 2: Color fundus photograph of the right eye (upper left) shows a 
yellowish-gray subfoveal lesion suggestive of choroidal neovascularization with specks 
of fresh subretinal hemorrhage. Early hyperfluoresence with intense late staining 
on fundus fluorescein angiography confirms the presence of predominantly classic 
choroidal neovascularization (upper right and lower right); blocked fluorescence 
corresponds to subretinal hemorrhage. Optical coherence tomography scan reveals 
the presence of a high reflective, spindle-shaped lesion in the subretinal area abutting 
the fovea with increased overlying retinal thickness (lower left).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  coherence   tomography (Figure 2, central column, middle). 
Monthly intravitreal ranibizumab injections were repeated 
twice. One month later, choroidal neovascularization had 
regressed and vision was improved to 6/36. The patient 
was followed up on a monthly basis. Three months later, 
vision was maintained but optical coherence tomography 
revealed a full-thickness macular hole (Figure 2, central 
column, below).
Case 3
A 69-year-old gentleman presented with bilaterally 
decreased vision over the previous few months. BCVA in 
the right eye was 6/9 and 6/60 in the left eye. Biomicro-
scopic examination of the fundus revealed choroidal neo-
vascularization in both eyes (left eye, Figure 4, upper left) 
which was confirmed on fundus fluorescein angiography 
(Figure 4, upper right and lower right). Optical coherence 
tomography showed subretinal fluid and cystoid macular 
edema (Figure 4, lower left) in the left eye. The patient 
underwent combination photodynamic therapy (50 J/cm2) 
and intravitreal ranibizumab 0.5 mg in the right eye and 
received intravitreal ranibizumab 0.5 mg in the left eye. 
One month later, intravitreal ranibizumab was repeated in 
both eyes. The patient was followed up on a monthly basis. 
Three months later, vision in the right eye improved to 
6/9 and worsened to FC 2 m in the left. Optical coherence 
tomography revealed foveal atrophy in the left eye (Figure 2, 
right column, lower).
Discussion
Various theories have been postulated to account for macular 
hole formation. Gass4 hypothesized that contraction of the 
prefoveal vitreous cortex caused focal tangential traction, 
leading to formation of idiopathic macular holes. Gaudric 
et al5 in an optical coherence tomography study concluded 
that vitreous traction may actually be oblique. Therefore, 
tangential and anterior-posterior transvitreal traction has 
been implicated in the development of idiopathic macular 
holes. Chung et al6 hypothesized that intravitreal injection 
can induce vitreous incarceration, causing vitreoretinal trac-
tion leading to the development of a macular hole. It is also 
postulated that ranibizumab itself can cause the macular 
hole by modulating the activity of choroidal neovasculariza-
tion and inducing contraction of the membrane, leading to 
exacerbation of tangential traction on the overlying retina.2 
Macular hole formation has been reported 20 days after 
photodynamic therapy.1 This reported eye had pre-existing 
posterior vitreous detachment. Macular hole formation fol-
lowing photodynamic therapy was attributed to choroidal 
swelling leading to dehiscence of the foveal pit, exacerbation 
of tangential traction by the laser administered over the fovea, 
or exacerbation of cystoid macular edema with coalescence 
of cysts, leading to full-thickness macular hole. In a report of 
macular hole formation following intravitreal triamcinolone 
acetonide injection for diabetic macular edema,7 the authors 
hypothesized that there was degeneration of the retinal cells, 
especially Muller cells, after prolonged edema.
In our patients, several possible mechanisms may have 
induced the development of macular hole, including those dis-
cussed above. Hence, to conclude, the possibility of develop-
ment of foveal atrophy and macular hole must be kept in mind 
before initiating combination therapy with photodynamic 
therapy and ranibizumab. However, larger studies with longer 
follow-up could unravel such adverse effects better.
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